TP53 and neoplasm: Notably, in a previous paper [22] we demonstrated that AdoMet reduced the proliferation of HCT 116p53−/− and uL3∆HCT 116p53−/− cells although, according to the literature, the lack of p53 expression is usually associated with loss of p53-dependent tumor-suppressive functions, making tumor cells more resistant to chemotherapy treatments [26].